This might be the death knell for Adam Feuerstein...seriously.
I have known AF (to my great regret) for 30+ years. He spent more that a decade as a Housing & Building analyst, working for Drexel Burnham if my memory serves me. I agree that Celsion could be the death-knell of his career in biotech. But like Cramer, he may have 9 lives and simply return to H&B which would be an opportune move since the sector is entering a multi-year uptrend.